Last updated: September 8, 2026
Methylnaltrexone bromide, marketed primarily as Relistor by Bausch Health’s Salix Pharmaceuticals, is an established peripheral mu-opioid receptor antagonist used to treat opioid-induced constipation (OIC). Its market is mature, prescription-driven, and exposed to generic substitution, payer controls, and declining opioid utilization in some segments. The product retains commercial value through chronic non-cancer pain use, advanced-illness care, multiple dosage forms, and physician familiarity, but its long-term growth is constrained by limited market expansion and potential generic entry.
Product-specific revenue is not consistently disclosed by Bausch Health. Relistor is reported within Salix Pharmaceuticals rather than as a separate public operating segment, making independent product valuation dependent on prescription data, transaction disclosures, and channel estimates.
What is methylnaltrexone bromide and how is Relistor used?
Methylnaltrexone bromide is a quaternary derivative of naltrexone. Its permanent positive charge limits central nervous system penetration, allowing it to block peripheral mu-opioid receptors in the gastrointestinal tract while generally preserving centrally mediated analgesia.
The U.S. Food and Drug Administration has approved Relistor for:
- Opioid-induced constipation in adults with advanced illness receiving palliative care when response to laxative therapy has been insufficient.
- Opioid-induced constipation in adults with chronic non-cancer pain.
- Opioid-induced constipation in pediatric patients in selected age and weight groups, following later label expansion.
Relistor is available in subcutaneous injection and oral tablet forms. The injection has particular relevance in palliative care and patients unable to take oral medication. Tablets address the larger chronic non-cancer pain market but compete directly with oral agents such as lubiprostone, naldemedine, and naloxegol.
| Product |
Active ingredient |
Route |
Main OIC segment |
Primary commercial positioning |
| Relistor injection |
Methylnaltrexone bromide |
Subcutaneous |
Advanced illness and selected chronic pain patients |
Rapid peripheral opioid antagonism; useful when oral therapy is unsuitable |
| Relistor tablets |
Methylnaltrexone bromide |
Oral |
Chronic non-cancer pain |
Maintenance treatment |
| Movantik |
Naloxegol |
Oral |
Chronic non-cancer pain |
Broad oral OIC competition |
| Symproic |
Naldemedine |
Oral |
Chronic non-cancer pain |
Strong gastrointestinal selectivity and chronic-use positioning |
| Amitiza |
Lubiprostone |
Oral |
Chronic non-cancer pain and other constipation indications |
Non-opioid secretagogue alternative |
Sources: FDA, 2024a; FDA, 2024b.
How large is the methylnaltrexone bromide market?
The addressable market is defined by opioid exposure, constipation severity, diagnosis rates, payer coverage, and the share of patients who fail or cannot tolerate conventional laxatives. The largest commercial pool is chronic non-cancer pain, while advanced-illness use is smaller but clinically differentiated.
Market growth is limited by several factors:
- Opioid prescribing has become more restrictive in the United States.
- Many patients are treated initially with inexpensive laxatives.
- Oral prescription competitors have established payer contracts.
- OIC treatment is often episodic rather than continuously reimbursed.
- Generic or authorized-generic entry could materially reduce net pricing.
The market has countervailing support. Opioids remain widely used in cancer, postoperative, palliative, and chronic pain settings. OIC can persist throughout opioid therapy, creating recurring demand among patients who receive effective treatment. The aging population and continued use of opioids in oncology and supportive care also support baseline demand.
Relistor’s most defensible segment is the patient population requiring an injectable option or a product with a differentiated clinical and prescribing history. Its weakest segment is price-sensitive chronic non-cancer pain, where oral alternatives and generic laxative regimens create substitution pressure.
What is the financial trajectory of Relistor?
Bausch Health does not generally disclose Relistor as a standalone revenue line in its public financial statements. The product is included in Salix Pharmaceuticals reporting, alongside larger products such as Xifaxan, Trulance, Plenvu and other gastrointestinal medicines. This limits direct assessment of Relistor revenue, gross margin and operating contribution.
The financial trajectory is best characterized as mature and cash-generative rather than high-growth:
| Financial driver |
Effect on Relistor |
| Chronic OIC prescriptions |
Supports recurring demand |
| Palliative-care injection use |
Protects a differentiated niche |
| Oral competition |
Limits volume and price growth |
| Generic entry |
Creates the largest downside risk |
| Bausch Salix infrastructure |
Supports commercial leverage and profitability |
| Opioid prescribing restrictions |
Constrains market expansion |
| Pediatric label expansion |
Adds a limited incremental population |
Bausch Health’s broader Salix business has been a major contributor to the company’s revenue and cash flow. Relistor is strategically useful because it fits the gastrointestinal portfolio and can be promoted through an existing specialty-commercial infrastructure. Its standalone importance is smaller than that of Xifaxan, but it can support portfolio retention, cross-selling and payer negotiations.
The product’s mature financial profile means that value depends more on duration of exclusivity and net price preservation than on large prescription growth. A modest increase in treated patients can be offset by rebates, formulary restrictions or lower-priced competition.
When does methylnaltrexone bromide lose exclusivity?
Relistor’s exclusivity position has several layers:
- FDA regulatory exclusivity tied to the original approval and later supplements.
- Composition-of-matter and active-ingredient patents.
- Formulation and dosage-form patents.
- Method-of-use patents covering treatment of OIC.
- Any pediatric exclusivity or patent-term extensions attached to listed patents.
The original FDA approval occurred in 2008 for the injection. The oral tablet approval followed in 2014. The principal composition-of-matter protection for methylnaltrexone is substantially older than the current product franchise, so the commercial protection period depends heavily on later formulation, use and dosage-form patents.
A fixed single “Relistor patent expiration date” is therefore misleading. Orange Book-listed patents can expire at different times, and a generic applicant may challenge one or more listed patents through a Paragraph IV certification. FDA approval timing also depends on the challenged patent claims, litigation outcomes and any settlement.
What patents protect Relistor?
Relistor protection has historically involved patent families covering:
- Methylnaltrexone compounds and salts.
- Pharmaceutical compositions containing methylnaltrexone bromide.
- Oral dosage forms.
- Treatment of opioid-induced constipation.
- Dosing regimens and patient populations.
- Injectable formulations and administration methods.
The relevant assignees and commercial rights have included Progenics Pharmaceuticals and later Salix Pharmaceuticals or affiliated Bausch entities. Patent ownership and Orange Book listing status can differ because not every patent in a broader patent family is listed for FDA purposes.
The key business issue is claim scope. A broad composition patent can block competing products using the same active ingredient. A narrower formulation or method patent may still delay entry, but it is more vulnerable to non-infringement and invalidity arguments.
A current diligence review should distinguish:
| Patent category |
Commercial importance |
Generic vulnerability |
| Composition of matter |
High if still enforceable |
Lower, because design-around is difficult |
| Salt or solid-state form |
Medium to high |
Depends on required active ingredient form |
| Oral formulation |
High for tablets |
Moderate to high |
| Injectable formulation |
High for injection products |
Depends on formulation overlap |
| Method of use |
Variable |
Higher if label carve-out is practical |
| Dosing regimen |
Variable |
Higher where alternative dosing is possible |
What is the Orange Book status of Relistor?
Relistor is an FDA-approved small-molecule drug product, not a biologic. Its relevant FDA reference listing is the Orange Book, and generic applicants would ordinarily use an abbreviated new drug application rather than a biosimilar pathway.
The Orange Book determines which patents are formally listed against the approved product and provides the framework for Paragraph IV certification. A listed patent does not guarantee enforceability or prevent generic approval indefinitely. The patent holder must bring infringement litigation within the statutory period to obtain the automatic stay of approval available under the Hatch-Waxman framework.
Regulatory exclusivity and patent exclusivity should be analyzed separately. FDA exclusivity can restrict approval of competing applications for a defined period, while patents can extend beyond that period. Later pediatric labeling may provide limited additional exclusivity but does not recreate the commercial value of the original approval.
Which companies compete with methylnaltrexone bromide?
Relistor competes across three levels.
Direct prescription OIC competitors
- Movantik, marketed by RedHill Biopharma after prior ownership by AstraZeneca.
- Symproic, marketed by subsidiaries of Shionogi.
- Amitiza, originally developed by Sucampo and marketed in collaboration with Takeda.
- Generic and over-the-counter laxatives, including polyethylene glycol, stimulant laxatives and stool softeners.
Indirect clinical competitors
Physicians may manage OIC by changing the opioid, reducing the dose, adding scheduled laxatives, or using non-opioid pain treatment. These approaches reduce the pool of patients eligible for or willing to use Relistor.
Competitive strengths and weaknesses
Relistor’s injection provides differentiation in palliative and advanced-illness settings. Its oral product is less differentiated because naldemedine and naloxegol are also designed to provide peripheral opioid antagonism without materially reversing analgesia.
| Factor |
Relistor position |
| Injectable option |
Strong |
| Chronic oral OIC differentiation |
Moderate |
| Palliative-care utility |
Strong |
| Payer leverage |
Dependent on formulary position |
| Price resilience |
Moderate before generic entry |
| Generic vulnerability |
High once substitutable ANDAs are approved |
Are there Paragraph IV challenges or generic launch risks?
No confirmed broad commercial generic launch of methylnaltrexone bromide had been established in the public information available through mid-2024. The principal generic risk remains an ANDA applicant challenging Orange Book-listed patents through Paragraph IV certification.
Potential launch scenarios are:
- No near-term generic entry because patents remain enforceable or litigation delays approval.
- A settlement allowing a future generic launch before the latest patent expiry.
- A negotiated license or authorized generic arrangement.
- At-risk launch after a court ruling or litigation settlement.
- Separate entry into oral and injectable presentations at different times.
The oral product is likely to face the greater commercial pressure because it is easier to compare with competing oral OIC therapies and may be more attractive to generic manufacturers. Injectable entry can require additional formulation, device, manufacturing and stability capabilities, which may narrow the field of credible competitors.
What manufacturing and intellectual-property barriers exist?
Methylnaltrexone bromide is a small molecule, so it does not face the cell-line, biosimilar comparability and clinical immunogenicity barriers associated with biologics. Manufacturing barriers are therefore lower than for monoclonal antibodies.
The main barriers are:
- Demonstrating pharmaceutical equivalence.
- Matching the approved dosage form and release characteristics.
- Establishing injectable quality and sterility.
- Securing reliable active pharmaceutical ingredient supply.
- Navigating Orange Book patents and regulatory exclusivity.
- Supporting abbreviated applications for multiple strengths and routes.
The injectable product is more operationally demanding than tablets because sterile manufacturing, container closure, stability and administration compatibility add cost. These requirements do not create biologic-level barriers, but they can delay entry and reduce the number of launch-capable manufacturers.
What litigation and settlement agreements affect Relistor?
Relistor’s commercial risk is primarily Hatch-Waxman litigation rather than biosimilar litigation. Publicly available information through mid-2024 did not establish a major ongoing biosimilar dispute because methylnaltrexone bromide is not regulated as a biologic.
Any meaningful patent litigation assessment should track:
- ANDA filings naming Relistor.
- Paragraph IV notices to the patent holder.
- District court complaints.
- Thirty-month stays of FDA approval.
- Patent settlements and licensed entry dates.
- Federal Circuit appeals.
- Changes to Orange Book patent listings.
A settlement can be commercially significant even when it does not produce an immediate generic launch. The key economic terms are the permitted entry date, product form covered, royalty obligations, authorized-generic rights and restrictions on launching competing presentations.
How strong is the methylnaltrexone bromide patent estate?
The estate is commercially meaningful but not comparable to a newly launched medicine with a long remaining composition-patent term. Its strength depends on later-expiring formulation and use claims rather than a single dominant molecule patent.
Overall assessment:
| Attribute |
Assessment |
| Active ingredient differentiation |
Low to moderate |
| Composition-patent durability |
Limited relative to newer products |
| Formulation protection |
Material, particularly for tablets and injection |
| Method-of-use protection |
Useful but more vulnerable to label carve-outs |
| Generic design-around risk |
Moderate |
| Biosimilar risk |
None |
| Manufacturing complexity |
Moderate for injection; low to moderate for tablets |
| Revenue durability |
Dependent on patent timing and payer retention |
What is the outlook for Relistor revenue?
Relistor is likely to remain a stable niche product within Salix rather than a major growth engine. Revenue can remain resilient if Bausch preserves access in palliative care, maintains favorable coverage for injection and limits substitution in chronic pain.
The downside case is a sharp decline after generic oral entry, followed by a slower decline if injectable competition arrives later. The upside case is a longer period without approved generics, continued opioid use in oncology and chronic pain, and incremental pediatric or institutional demand.
Relistor’s value to Bausch is therefore broader than standalone sales. It contributes to the density of the Salix gastrointestinal portfolio, supports sales-force productivity and can improve the economics of the company’s specialty-pharmaceutical infrastructure.
Key Takeaways
- Methylnaltrexone bromide is a mature small-molecule OIC therapy marketed primarily as Relistor.
- Its strongest commercial position is injectable use in palliative and advanced-illness care.
- Oral Relistor faces direct competition from Movantik, Symproic, Amitiza and low-cost laxatives.
- Bausch does not consistently disclose Relistor revenue separately, limiting precise product-level financial modeling.
- The patent estate relies on composition, formulation, dosage-form and method-of-use protection with different expiration profiles.
- The product has no biosimilar risk, but it has conventional generic and Paragraph IV risk.
- Generic entry into tablets would likely cause greater price and volume pressure than initial entry into injection.
- Relistor is best valued as a mature, cash-generative Salix product with exclusivity-driven downside risk.
FAQs
Is methylnaltrexone bromide a biologic or a small molecule?
Methylnaltrexone bromide is a small-molecule drug. Competitors would use the ANDA pathway for generic approval, not the biosimilar pathway.
Does Relistor reverse opioid pain relief?
Relistor is designed to act primarily on peripheral mu-opioid receptors. Its clinical purpose is to relieve opioid-induced constipation without materially reversing centrally mediated analgesia when used according to labeling.
Which Relistor dosage form has the greatest generic risk?
The oral tablet generally has the greatest generic risk because it is easier to compare with other oral OIC products and can be manufactured without sterile injectable infrastructure.
Is Relistor more differentiated than Movantik or Symproic?
Relistor is most differentiated by its subcutaneous injection and established role in advanced illness. Its oral product has less differentiation because Movantik and Symproic also target peripheral opioid effects.
Can a generic company launch Relistor before every patent expires?
A generic company may launch before all listed patent expirations if it prevails in litigation, reaches a settlement permitting early entry, obtains a license, or launches at risk after regulatory approval.
References
-
U.S. Food and Drug Administration. (2024a). Relistor (methylnaltrexone bromide) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Bausch Health Companies Inc. (2024). Annual report for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984. Pub. L. No. 98-417.
-
U.S. Food and Drug Administration. (2024c). Abbreviated new drug application approvals and generic drug guidance. FDA.
